- 5 Chana R, Brunskill N. Thiazolidinediones inhibit albumin uptake by proximal tubular cells through a mechanism independent of peroxisome proliferator activated receptor gamma. Am J Nephrol 2006; 26:67–74
- 6 Deschenes G, Feraille E, Doucet A. Mechanisms of oedema in nephrotic syndrome: old theories and new ideas. Nephrol Dial Transplant 2003; 18:454–456.
- Benetos A, Adamopoulos C, Bureau J-M et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation 2002; 105:1202–1207.
- 8 Safar ME, Blacher J, Pannier B et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39:735–738.
- 9 McEniery CM, Schmitt M, Qasem A et al. Nebivolol increases arterial distensibility in vivo. Hypertension 2004; 44:305–310.
- 10 Covic A, Goldsmith D, Gusbeth-Tatomir P, Buhaescu I, Covic M. Successful renal transplantation decreases aortic stiffness and increases vascular reactivity in dialysis patients. *Transplantation* 2003; 76:1573–7.
- 11 Feig DI, Mazzali M, Kang D-H et al. Serum uric acid: A risk factor and a target for treatment? J Am Soc Nephrol 2006; 17:S69–73.
- 12 Watanabe S, Kang D-H, Feng L et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40:355–360.
- 13 Johnson R, Titte S, Cade J, Rideout B, Oliver W. Uric acid, evolution and primitive cultures. Semin Nephrol 2005; 25:3–8.
- 14 Pirsch J, Miller J, Deierhoi M, Vincenti F, Filo R. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63:977–83.
- 15 The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. *Transplantation* 1996; 61:1029–37.
- 16 Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised

- multicentre study. Lancet 2000; 356:194-202.
- 17 Nashan B, Moore R, Amlot P, Schmidt A-G, Abeywickrama K, Soulillou J-P. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350:1193–1198.
- 18 Hariharan S, Mcbride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. *Kidney Int* 2002; 62:311–318.
- 19 Johnson R, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. *Transplantation* 2001; 72:777–86.
- 20 Borrows R, Loucaidou M, Tromp JV et al. Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. Am J Transplant 2004; 4:1845–51.
- 21 Tan HP, Kaczorowski DJ, Basu A et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006; 6:2409–2417.
- 22 Nankivell BJ, Borrows RJ, Fung CL-S, O'Connell PJ, Allen RDM, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349:2326–2333.
- 23 Dudley C, Pohanka E, Riad H et al. Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: The 'creeping creatinine' study. Transplantation 2005; 79:466–75.
- 24 Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361:2024–2031.
- 25 Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW. Post-transplant de novo malignancies in renal transplant recipients: the past and present. *Transplant International* 2006; 19:607–620.
- 26 Smith C, Silva-Gane MD, Chandna S, Warwicker P, Greenwood R, Farrington K. Choosing not to dialyse: evaluation of planned non-dialytic management in a cohort of patients with end-stage renal failure. Nephron Clinical Practice 2003; 95:40–46.

PAST PRESIDENTS

Professor William Beilby (1783-1849)

In the days of Beilby and the famous Simpsons, Sir James Young Simpson and his equally distinguished nephew Sir Alexander Russell Simpson, midwifery was a specialty of medicine. The term 'Obstetrics' was not yet in use. In fact, the British College of Obstetrics and Gynaecology (known today as The Royal College of Obstetricians and Gynaecologists) was only founded by William Blair-Bell and Sir William Fletcher-Shaw in 1929.

Little is known about Beilby beyond the fact that he was born in Sheffield, and in 1807, apparently with no intention of becoming a doctor, went into the linen trade in Dublin. However, six years later, he entered the medical school in Edinburgh, qualifying after three years. His MD was on an obstetric topic and that remained his special interest for the rest of his professional life. In fact, his official title was 'Physician Accoucheur to the New Town Dispensary'.

President of the College from 1844–46, almost the only paper extant from that time is a letter to him from Sir James Young Simpson about an unseemly row he had had in a patient's house with the surgeon Mr Syme, offering an explanation and apologies. (It will

be recalled that Simpson was himself to become President, from 1850–52.) On a happier note it was during Beilby's Presidency that the Great Hall of the College was built and officially opened, the President's address drawing heavily on Sibbald's autobiography.

Beilby was a devoutly evangelical Christian, deeply involved with what was then known as the Evangelical Alliance as well as being First President of a Medical Missionary Society, one of several springing up at that time of missionary outreach, particularly to the Indian subcontinent and Africa.

Derek Doyle Obituaries Editor, The Journal RCPE